Neutralizing antibodies and cellular immune response after two doses of inactivated SARS-CoV-2 vaccine in China.

Autor:	Yan LN; State Key Laboratory of Virology, School of Public Health, Wuhan University, Wuhan, P.R. China., Zhao ZX; Department of Laboratory Medicine, Linyi People's Hospital, Linyi, Shandong, P.R. China., Wang ZD; School of Public Health, Xi'an Medical University, Xi'an, P.R. China., Xiao X; State Key Laboratory of Virology, School of Public Health, Wuhan University, Wuhan, P.R. China., Liu PP; State Key Laboratory of Virology, School of Public Health, Wuhan University, Wuhan, P.R. China., Zhang WK; State Key Laboratory of Virology, School of Public Health, Wuhan University, Wuhan, P.R. China., Gu XL; State Key Laboratory of Virology, School of Public Health, Wuhan University, Wuhan, P.R. China., Li B; State Key Laboratory of Virology, School of Public Health, Wuhan University, Wuhan, P.R. China., Yu LP; School of Nursing, Wuhan University, Wuhan, P.R. China., Yu XJ; State Key Laboratory of Virology, School of Public Health, Wuhan University, Wuhan, P.R. China.
Jazyk:	angličtina
Zdroj:	Expert review of vaccines [Expert Rev Vaccines] 2022 Oct; Vol. 21 (10), pp. 1465-1473. Date of Electronic Publication: 2022 Jul 29.
DOI:	10.1080/14760584.2022.2104714
Abstrakt:	Background: As of 2022, inactivated SARS-CoV-2 vaccines had been used in more than 91 countries. However, limited real world information was available on the immune responses of the inactivated SARS-CoV-2 vaccine. Methods: We used SARS-CoV-2 pseudovirues to determine the neutralizing antibodies (NAbs) to wild type and several global variants and utilized enzyme-linked immunosorbent assay to investigate IFN-γ-secreting T-cell responses to SARS-CoV-2 among 240 vaccinated individuals after two doses of inactivated vaccine in China. Results: A majority of the vaccinated (>90%) developed robust NAbs and T-cell responses to SARS-CoV-2 in the first two months after the second dose. After six months, only 37.0% and 44.0% of vaccinees had NAbs and T-cell immunity to SARS-CoV-2, respectively. Immune serum retained most of its neutralizing potency against the Alpha and Iota variants, but lost significant neutralizing potency against the Beta, Kappa, Delta, and Omicron variants. Only 40% of vaccine-sera retained low-level neutralization activities to Omicron, with a 14.7-fold decrease compared to the wild type. Conclusion: The inactivated SARS-CoV-2 vaccine stimulated robust NAbs and T-cell immune responses in the first two months after the second dose but the immune effect dropped rapidly, highlighing that a third dose or additional booster immunizations may be required to boost immunity against SARS-CoV-2.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu